http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102055390-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-484 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-79 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-745 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21007 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-79 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-66 |
| filingDate | 2017-12-28^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-12-12^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-12-12^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102055390-B1 |
| titleOfInvention | Fusion peptide comprising clot-targeting peptide, ferritin fragment and thrombolytic peptide and its uses |
| abstract | The present invention relates to a fusion peptide comprising a thrombus-target peptide, a ferritin fragment and a thrombolytic peptide, and a use thereof, and more particularly, to a fusion peptide in which a thrombus-target peptide, a ferritin fragment and a thrombolytic peptide are connected in turn. It relates to a composition for preventing or treating thrombotic disease, which comprises as an active ingredient. CLT-sFt-μPn DCNC according to the present invention is a plasmin-based new thrombolytic nanocage that targets sites where thrombi exists, low sensitivity to inhibitors present in the circulatory system, both arterial and venous thrombi It has strong pharmacological activity and no bleeding side effects, which can be very useful for preventing or treating thrombotic disease. |
| priorityDate | 2017-01-06^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 537 of 537.